Inhibiting CD36 to overcome resistance to Tykerb in HER2-positive breast cancer

By Claire Quang | Jan 28, 2020 | 8:34 PM GMT

DISEASE CATEGORY: Cancer

INDICATION: Breast cancer

Inhibiting CD36, a fatty acid transporter, could treat HER2-positive breast cancer and sensitize tumors resistant to

Read the full 202 word article

How to gain access

Continue reading with a
two-week free trial.